Application of circTTC39C inhibitor in improving hepatocellular carcinoma targeted drug resistance and reducing immune escape
By combining circTTC39C inhibitors with circTTC39C, the problems of drug resistance and immune escape in hepatocellular carcinoma patients have been solved, the sensitivity of liver cancer cells to lenvatinib has been improved, and a new treatment and diagnostic strategy has been provided, which has important clinical application value.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
- Filing Date
- 2026-04-21
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have limitations in improving the sensitivity of targeted drugs for hepatocellular carcinoma and reducing immune escape, especially in addressing drug resistance and immune escape issues in hepatocellular carcinoma patients. Existing methods, such as RNA interference technology, face problems of insufficient targeting and poor in vivo stability in clinical applications.
Using a circTTC39C inhibitor, a specific antisense oligonucleotide (ASO) is designed to bind to circTTC39C, thereby reducing its expression and increasing the sensitivity of liver cancer cells to lenvatinib. A pharmaceutical composition is also provided, which includes a circTTC39C inhibitor and other drugs such as antiviral drugs, chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs.
It significantly improves the sensitivity of liver cancer cells to lenvatinib, delays or reverses the development of drug resistance, provides new treatment strategies and diagnostic basis, and offers new treatment options for HCC patients, especially those who have failed existing treatments, which has important clinical application value.
Smart Images
Figure CN122398843A_ABST